{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:32:16Z","timestamp":1793734336411,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.01.012","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T09:52:38Z","timestamp":1235469158000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["The effect of pramipexole on mood and motivational symptoms in parkinson's disease: A meta-analysis of placebo-controlled studies"],"prefix":"10.1016","volume":"31","author":[{"given":"Albert F.G.","family":"Leentjens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Koester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Fruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Toby S.","family":"Shephard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.G.","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.01.012_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. DSM-IV-TR","year":"2000"},{"key":"10.1016\/j.clinthera.2009.01.012_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ageing\/28.4.341","article-title":"Measuring the impact of Parkinson's Disease Quality of Life questionnaire","volume":"28","author":"Hobson","year":"1999","journal-title":"Age Ageing"},{"key":"10.1016\/j.clinthera.2009.01.012_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s004150050131","article-title":"The correlation of depression with functional activity in Parkinson's disease","volume":"244","author":"Liu","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","article-title":"Range of neuropsychiatrie disturbances in patients with Parkinson's disease","volume":"67","author":"Aarsland","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2009.01.012_bib6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneur.1995.00540360042014","article-title":"Neuropsychological impairment in Parkinson's disease with and without depression","volume":"52","author":"Troster","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib7","first-page":"784","article-title":"Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease","volume":"52","author":"Weintraub","year":"2004","journal-title":"J Am Ceriatr Soc"},{"key":"10.1016\/j.clinthera.2009.01.012_bib8_1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/01.wnl.0000230572.07791.22","article-title":"Dissociating apathy and depression in Parkinson's disease","volume":"67","author":"Kirsch-Darrow","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib8_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/01.wnl.0000230572.07791.22","article-title":"Dissociating apathy and depression in Parkinson's disease","volume":"67","author":"Kirsch-Darrow","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson's disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"J Neuropsych Clin Neurosci"},{"key":"10.1016\/j.clinthera.2009.01.012_bib10","first-page":"141","article-title":"Pharmacology of prami-pexole, a dopamine D3-prefernng agonist useful in treating Parkinson's disease","volume":"21","author":"Piercey","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.npp.1300677","article-title":"Antidepressant-like effect of D(2\/3) receptor-, but not D(4) receptor-activation in the rat forced swim test","volume":"30","author":"Basso","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00041444-199912000-00005","article-title":"Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder","volume":"9","author":"Dikeos","year":"1999","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.clinthera.2009.01.012_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/jnp.17.2.214","article-title":"Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole","volume":"17","author":"Lemke","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2009.01.012_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00023210-200317130-00003","article-title":"Pramipexole in routine clinical practice: A prospective observational trial in Parkinson's disease","volume":"17","author":"Reichmann","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2009.01.012_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergohde in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study","volume":"10","author":"Rektorov\u00e1","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multi-center parallel-group randomized study","volume":"235","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib17","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","article-title":"Unified Parkinson's Disease Rating Scale","author":"Fahn","year":"1987"},{"key":"10.1016\/j.clinthera.2009.01.012_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergohne dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neu rosu rg Psychiatry"},{"key":"10.1016\/j.clinthera.2009.01.012_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1468-1331.1998.530235.x","article-title":"A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease","volume":"5","author":"Wermuth","year":"1998","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2009.01.012_bib22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease","volume":"49","author":"Guttman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study","volume":"278","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.01.012_bib24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial","volume":"20","author":"Moller","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib25","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.20555","article-title":"Antidepressant studies in Parkinson's disease: A review and meta-analysis","volume":"20","author":"Wemtraub","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/mds.10538","article-title":"Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergohde, and placebo on Parkinsonian tremor","volume":"18","author":"Navan","year":"2003","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.012_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1017\/S0317167100046230","article-title":"The neurobiological substrates of depression in Parkinson's disease: A hypothesis","volume":"11","author":"Fibiger","year":"1984","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.clinthera.2009.01.012_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00536.x","article-title":"Depression in Parkinson's disease-a review","volume":"113","author":"Lieberman","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2009.01.012_bib29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.01.012_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2007-959188","article-title":"Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy [in German]","volume":"75","author":"Buchwald","year":"2007","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.1016\/j.clinthera.2009.01.012_bib31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson's disease: Critique and recommendations","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib32","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/mds.22229","article-title":"Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations","volume":"23","author":"Leentjens","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib33","doi-asserted-by":"crossref","first-page":"185192","DOI":"10.1002\/mds.870110212","article-title":"Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale","volume":"11","author":"Louis","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2009.01.012_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","article-title":"Unified Parkinson's Disease Rating Scale characteristics and structure","volume":"9","author":"Martinez-Mart\u00edn","year":"1994","journal-title":"Mov Disord"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:58Z","timestamp":1758962878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0149291809000265"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of pramipexole on mood and motivational symptoms in parkinson's disease: A meta-analysis of placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}